Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas

Clinical trial NCT01678352 · COMPLETED

Trial details

NCT number: NCT01678352
Sponsor: Frank Lieberman
Status: COMPLETED
Phase: Early Phase 1
Study type: INTERVENTIONAL

High Risk WHO Grade II Glioma Recurrent/Post-Chemotherapy WHO Grade II Glioma

Start date: 2012-10-01
Primary completion: 2017-11-08
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.